junctive potassium iodide after radioactive iodine (131-I) treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab 57:250, 1983.
51. Reinwein D, Schaps D, Berger H, Hackenberg K, Horster FA, Klein E, Von Zur Muhlen A, Wendt RU, Wildmeister W: Hypothyreoserisyiko nach fraktionierter Radiojodtherapie. Dtsch Med Wochenschr 98:1789, 1973.
52. Rapoport B, Caplan R, DeGroot L: Low-dose sodium iodide 131-I therapy in Graves’ disease. J Amer Med Assn 224:1610, 1973.
53. Roudebush CP, Hoye KE, DeGroot LJ: Compensated low-dose 131-I therapy of Graves’ disease. Ann Intern Med 87:441, 1977.
54. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ: Long-term follow-up study of compensated low-dose 131-I therapy for Graves’ disease. N Engl J Med 311:426-432, 1984.
55. Glennon JA, Gordon ES, Sawin CT: Hypothyroidism after low- dose I131 treatment of hyperthyroidism. Ann Intern Med 76:721, 1972.
56. Saito S, Sakurada T, Yamamoto M, Yoshida K, Kaise K, Kaise N, Yoshinaga K: Long term results of radioiodine 131-I therapy in 331 patients with Graves’ disease. Tokyo J Exp Med 132:1-10, 1980.
57. DeGroot LJ, Mangklabruks A, McCormick M: Comparison of RA 131-I treatment protocols for Graves’ disease. J Endocrinol Invest 13:111-118, 1990.
57.1. Berg G, Michanek A, Holmberg E, Nystrom E. Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study. J Intern Med 239:165-171, 1996.
57.2. Rini JN, Vallabhajosula S, Zanzonico P, Hurley JR, Becker DV, Goldsmith SJ. Thyroid uptake of liquid versus capsule 131-I tracers in hyperthyroid patients treated with liquid 131-I. Thyroid 9:347, 1999
57.3-Schiavo M, Bagnara MC, Calamia I, Bossert I, Ceresola E, Massaro F, Giusti M, Pilot A, Pesce G, Caputo M, Bagnasco M.A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves’ disease: need to retarget the radiation committed dose to the thyroid. J Endocrinol Invest. 2011 Mar;34(3):201-5. Epub 2010 Dec 15
57.4 Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH Striving for euthyroidism in radioiodine therapy of Graves’ disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid. 2011 Jun;21(6):647-54. doi: 10.1089/thy.2010.0348. Epub 2011 May 12
58. Wise PH, Burnet RB, Ahmad A, HardingPE: Intentional radioiodine ablation in Graves’ disease. Lancet 2:1231, 1975.
58.2. Allahabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA. Radioiodine treatment of hyperthyroidismâ€”prognostic factors for outcome. J Clin Endocrinol Metab 86:3611-3617, 2001.
58.21 Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E. J Clin Endocrinol Metab. 2010 Jan;95(1):201-8 Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
58.3: Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism.J Clin Endocrinol Metab. 2003 Mar;88(3):978-83.
58.31 Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L.Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab. 2006 Aug;91(8):2946-51.
58.4 Santos RB, Romaldini JH, Ward LS A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (¹³¹I) doses for Graves disease treatment.Clin Nucl Med. 2012 Mar;37(3):241-4.
59. Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, Fenzi GF, Pinchera A: A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves’ hyperthyroidism. J Endocrinol Invest 13:513-520, 1990.
59.1. Glinoer D, Verelst J. Use of 131-Iodine for the treatment of hyperthyroidism in adults. Annales d Endocrinologie 57:177-185, 1996.
59.2 Nakazato N, Yoshida K, Mori K, Kiso Y, Sayama N, Tani J-I, et al. 1999 Antithyroid drugs inhibi